Måndag 8 Juni | 20:10:01 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2027-02-24 08:30 Bokslutskommuniké 2026
2026-11-02 12:00 Kvartalsrapport 2026-Q3
2026-08-05 12:00 Kvartalsrapport 2026-Q2
2026-05-31 - Kvartalsrapport 2026-Q1
2026-05-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2026-05-26 - Extra Bolagsstämma 2026
2026-05-26 - Årsstämma
2026-03-27 - Bokslutskommuniké 2025
2025-11-14 - Kvartalsrapport 2025-Q3
2025-08-01 - Kvartalsrapport 2025-Q2
2025-05-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2025-05-26 - Årsstämma
2025-05-22 - Kvartalsrapport 2025-Q1
2025-03-27 - Bokslutskommuniké 2024
2024-12-30 - Extra Bolagsstämma 2025
2024-10-24 - Kvartalsrapport 2024-Q3
2024-10-04 - Extra Bolagsstämma 2024
2024-07-18 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2024-04-25 - Årsstämma
2024-04-18 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2023-04-26 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-12-14 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-14 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-27 - Extra Bolagsstämma 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-14 - Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Group bygger på strategiska förvärv som syftar till att driva tillväxt och diversifiera risker. Koncernen omfattar tre verksamhetsområden. Magle Chemoswed, en kontraktsutvecklings- och tillverkningsorganisation (CDMO). Magle PharmaCept, ett försäljnings- och marknadsföringsföretag för utveckling och direktförsäljning av koncernens medicintekniska produkter, och Magle Biopolymers A/S, en specialiserad tillverkningsorganisation för Dextran-teknologi.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-06-07 19:08:00

Magle Chemoswed Holding AB (publ) ("Magle" or the "Company") provides an update regarding its financing arrangements and ongoing discussions with key stakeholders.

Danske Bank Facility Maturing on 30 June 2026
The Company currently has a SEK 32.5 million credit facility with Danske Bank A/S that forms part of the Company's working capital financing arrangements. The facility is scheduled to mature on 30 June 2026 and is currently drawn.

The Company has been informed by Danske Bank A/S that the facility will not be renewed upon maturity.

As a result, the Company is engaged in discussions regarding alternative financing arrangements ahead of the maturity date.

Status of Bondholder Bridge Financing
As previously announced on 27 May 2026, the Company entered into a bridge loan facility agreement (the "Bridge Loan Agreement") with certain bondholders representing approximately 73.8 percent of the adjusted nominal amount under the Company's outstanding SEK 350,000,000 senior secured floating rate bonds (ISIN SE0025197403).

The Bridge Loan Agreement provides for financing of up to SEK 60 million, of which SEK 25 million has been drawn by the Company.

The remaining amount of up to SEK 35 million remains subject to certain conditions, including a broader agreement being reached between the Company, its major shareholders and relevant bondholders. As no such agreement has yet been reached, the Company cannot currently rely on access to the remaining undrawn amount as refinancing of the maturing Danske Bank facility.

Ongoing Discussions
The Company is engaged in active discussions with its major shareholders and representatives of the bondholders, with the objective of reaching a comprehensive financing solution prior to the maturity of the Danske Bank facility on 30 June 2026.

The Company and its stakeholders are treating these discussions with urgency and remain focused on achieving a solution that supports the Company's continued operations and long-term development.

The Company will provide further information as appropriate.